MacroGenics | MGNX - Operating Expenses


MacroGenics reported $67M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Genmab DKK 565M 38M Jun/2025
Geron USD 58.8M 2.31M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
MacroGenics USD 67M 8M Sep/2025
Merck USD 10.16B 558M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Xencor USD 81.86M 13.35M Dec/2025